Oxford BioDynamics a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory genome architecture for use within the pharmaceutical and biotechnology industry, announced the appointment of Paul Stockdale as CFO.
Stockdale is expected to join the Company 15 September 2017 and will be appointed to the Board of Directors in due course.
Stockdale succeeds Katie Long who is returning to her role within Tessera Investment Management Limited (Tessera), having established and led OBD’s finance function over the previous 9 months and during the Company’s IPO.
Long will step down from the Board on 30 June 2017 and will support OBD on an interim basis in the transitional period.
Stockdale joins the Company from e-Therapeutics, where he has held the position of Financial Controller since January 2012. During this time he has worked closely with the CFO and has been responsible for internal and external financial reporting and developing and maintaining financial and operational systems.
Stockdale is a Chartered Accountant and was a Senior Manager at Deloitte, where he worked from 1996 until 2004. Following this, he worked in finance and operations management in the charitable and automotive sectors. He read Natural Sciences at St John's College, University of Cambridge.
Christian Hoyer Millar, CEO at Oxford BioDynamics, said: "We are delighted to welcome Paul Stockdale to the Company. Paul's extensive financial management experience, including his recent experience in another public company focused on drug discovery, will be important as OBD strides towards becoming the industry standard for epigenetic biomarker discovery.”
